Literature DB >> 24631532

MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET.

Lijun Duan1, Xiaofang Hao2, Zhiyong Liu3, Yang Zhang4, Guangling Zhang5.   

Abstract

Dysregulation of the REarranged during Transfection proto-oncogene (RET) pathway and microRNA (miRNAs) are crucial for the development of medullary thyroid carcinomas (MTC). Here we demonstrate that miR-129-5p is down-regulated in MTC tissues and cell lines and inhibits RET expression by directly binding its 3' untranslated regions. Ectopic expression of miR-129-5p significantly decreases cell growth, induces apoptosis and suppresses migration ability in MTC cells through decreasing the phosphorylated AKT, thus functioning as a tumor suppressor. These findings give new clues for understanding MTC carcinogenesis and may help in developing a therapeutic approach for the treatment of RET-activated MTC.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell apoptosis; Cell growth; Cell migration; Medullary thyroid carcinoma; MiR-129-5p; REarranged during Transfection proto-oncogene

Mesh:

Substances:

Year:  2014        PMID: 24631532     DOI: 10.1016/j.febslet.2014.03.002

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  32 in total

1.  Norcantharidin induces autophagy-related prostate cancer cell death through Beclin-1 upregulation by miR-129-5p suppression.

Authors:  Wenjun Xiao; Bo Dai; Yao Zhu; Dingwei Ye
Journal:  Tumour Biol       Date:  2015-12-05

2.  A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma.

Authors:  Huan Chen; Xiangzhen Liu; Zhenning Jin; Chenyu Gou; Minglu Liang; Li Cui; Xinyuan Zhao
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.

Authors:  Jingyi Cao; Qichao Wang; Gang Wu; Shasha Li; Qian Wang
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

Review 4.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 5.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

6.  MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis.

Authors:  Li Xiao; Xun Zhou; Fuyou Liu; Chun Hu; Xuejing Zhu; Ying Luo; Ming Wang; Xiaoxuan Xu; Shikun Yang; Yashpal S Kanwar; Lin Sun
Journal:  Lab Invest       Date:  2015-05-11       Impact factor: 5.662

7.  MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in atherosclerosis.

Authors:  Zhaohua Geng; Fei Xu; Yiguan Zhang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

8.  MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2.

Authors:  Dan Yu; Guang-Hong Han; Xue Zhao; Xueshibojie Liu; Kai Xue; Di Wang; Cheng-Bi Xu
Journal:  Cell Oncol (Dordr)       Date:  2019-12-28       Impact factor: 6.730

9.  Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.

Authors:  A Valentino; A Calarco; A Di Salle; M Finicelli; S Crispi; R A Calogero; F Riccardo; A Sciarra; A Gentilucci; U Galderisi; S Margarucci; G Peluso
Journal:  Oncogene       Date:  2017-07-03       Impact factor: 9.867

Review 10.  The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.

Authors:  S Pishkari; M Paryan; M Hashemi; E Baldini; S Mohammadi-Yeganeh
Journal:  J Endocrinol Invest       Date:  2017-07-31       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.